Welcome to CEA Life Sciences Division website!
The Life Sciences Division (‘DSV’) is part of a public-benefit technological research hub that specializes in a number of research disciplines: from radiation biology and environmental nuclear toxicology through to medical imaging, large-scale biology and protein engineering, and back to bioenergies, biotechnologies, and more.
À votre rencontre
du 24/05/2013au 24/05/2013 Symposium of the launch of the Infectious Disease Models and Innovative Therapies (IDMIT) project
The aim of the project is to develop preclinical research in the field of infectious disease prevention and treatment by establishing a unique European research infrastructure with core facilities for monitoring diseases and the safety and efficacy of vaccines and treatments in relevant animal models of human infections.
À découvrir
Prositon
The unit acts as a hub interfacing radiation biology and toxicology laboratories with experts from the radiation protection industry À la une
CEA
Tuesday 23 April 2013
Theranexus: boosting the effectiveness of psychotropics
CEA The start-up Theranexus, a spin-off from the CEA, was launched on March 19. Its objective: to propose an adjuvant treatment [1] to be given in addition to psychotropic [2] medications that will augment their effectiveness or, in diminished doses, reduce their undesirable effects. Theranexus will be engaged in a large part of the product chain, from preclinical research to phase 2 clinical trials.
En savoir plus
Theranexus: boosting the effectiveness of psychotropics
CEA The start-up Theranexus, a spin-off from the CEA, was launched on March 19. Its objective: to propose an adjuvant treatment [1] to be given in addition to psychotropic [2] medications that will augment their effectiveness or, in diminished doses, reduce their undesirable effects. Theranexus will be engaged in a large part of the product chain, from preclinical research to phase 2 clinical trials.
En savoir plus
© L Simonneau/Inserm
Tuesday 02 April 2013
Producing new neurons under all circumstances: just a mouse away…
Improving neuron production in elderly persons presenting with a decline in cognition is a major challenge facing an ageing society and the emergence of neuro-degenerative conditions such as Alzheimer’s disease. INSERM and CEA researchers recently showed that the pharmacological blocking of the TGFβ molecule improves the production of new neurons in the mouse model. These results incentivise the development of targeted therapies enabling improved neuron production to alleviate cognitive decline in the elderly and reduce cerebral lesions caused by radiotherapy. The research is published in the journal EMBO Molecular Medicine.
En savoir plus
Producing new neurons under all circumstances: just a mouse away…
Improving neuron production in elderly persons presenting with a decline in cognition is a major challenge facing an ageing society and the emergence of neuro-degenerative conditions such as Alzheimer’s disease. INSERM and CEA researchers recently showed that the pharmacological blocking of the TGFβ molecule improves the production of new neurons in the mouse model. These results incentivise the development of targeted therapies enabling improved neuron production to alleviate cognitive decline in the elderly and reduce cerebral lesions caused by radiotherapy. The research is published in the journal EMBO Molecular Medicine.
En savoir plus
CEA
Friday 22 March 2013
Quantum dot: a promising new imaging agent
The drawback to current optical imaging markers is their short life. Researchers are now developing fluorescent nanocrystals (quantum dots) to supplant these markers. A team from the CEA-iBiTec-S, in collaboration with the CEA-I2BM and ESPCI [1], has developed a new surface chemistry for these particularly effective nanoparticles.
En savoir plus
Quantum dot: a promising new imaging agent
The drawback to current optical imaging markers is their short life. Researchers are now developing fluorescent nanocrystals (quantum dots) to supplant these markers. A team from the CEA-iBiTec-S, in collaboration with the CEA-I2BM and ESPCI [1], has developed a new surface chemistry for these particularly effective nanoparticles.
En savoir plus